“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”
Molecure is a clinical-stage biotechnology company. It uses its medicinal chemistry and biology capabilities to discover and develop first-in-class small molecule drug candidates that directly modulate the function of RNA and underexplored protein targets designed to treat multiple incurable diseases.
There remain serious unmet medical needs in the treatment of inflammatory and fibrotic diseases such as sarcoidosis, idiopathic pulmonary fibrosis and non-alcoholic steatohepatitis. Additionally, there is a constant need for new, targeted cancer treatments. The development of drugs which act through novel mechanisms of action could address these problems.
Managing Director - Head of Content, Healthcare
Marcin Szumowski
CEO
Nicolas Beuzen
Director of business development & licensing
Slawomir Broniarek
CFO
Forecast net debt (PLNm)
N/A
Forecast gearing ratio (%)
N/A
| % | 1M | 3M | 12M |
|---|---|---|---|
| Actual | 10.0 | 49.8 | (29.8) |
| Relative | 15.8 | 56.2 | (12.8) |
| 52 week high/low | 30.8gr/12.7gr |
As presented at its R&D day in December 2022, Molecure has now initiated the clinical trial for its second candidate, OATD-02. This Phase I trial is an open-label, multi-centre, first-in-human, dose-escalation study. The company will target cancers where immune checkpoint inhibitors (ICIs) have had limited success, an area where we believe OATD-02/ICI combinations could have an impact. In our view, this milestone supports Molecure’s development strategy and we expect an update on this trial in H223. The company also has pre-clinical animal model data for OATD-01 for the treatment of sarcoidosis, which suggests potential use in non-alcoholic steatohepatitis, a fibrotic disease with unmet need.
| Y/E Dec | Revenue (PLNm) | EBITDA (PLNm) | PBT (PLNm) | EPS (fd) (gr) | P/E (x) | P/CF (x) |
|---|---|---|---|---|---|---|
| 2020A | 124.9 | 73.9 | 112.0 | 745.0 | 2.7 | 4.9 |
| 2021A | 1.2 | (13.5) | (11.0) | (79.0) | N/A | N/A |
| 2022E | N/A | N/A | N/A | N/A | N/A | N/A |
| 2023E | N/A | N/A | N/A | N/A | N/A | N/A |
Get access to the very latest content matched to your personal investment style.
